|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Since genetic factors could play a role in determining the occurrence of these problems, the aim of the present study was to investigate whether possible functional polymorphisms among DRD2 and ANKK1 genes are associated with the risk of developing dyskinesia and motor fluctuations in Parkinson's disease patients.
|
23171335 |
2012 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We assessed whether allelic variants of dopamine D2 receptors (DRD2), catechol-O-methyltransferase (COMT) and dopamine transporter (DAT) were associated with the development of ICDs in PD.
|
22113132 |
2012 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Antipsychotics and serotoninergic antidepressants may potentially attenuate PD risk, and lithium and bupropion may augment risk, through MAPT, GBA, CCDC62, HIP1R, BDNF, and DRD2 transcription, with MAPT, GBA, and CCDC62 being strongly associated with PD risk in recent meta-analyses.
|
22507762 |
2012 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Among non-Hispanic whites, homozygous carriers of Taq1A DRD2 (rs1800497) polymorphism had an increased risk of PD compared to homozygous wildtype carriers (OR=1.5, 95% CI 1.0-2.3).
|
21663922 |
2011 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The DRD2 rs1800497 and DRD4 rs1800955 polymorphisms showed no association with PD.
|
21781348 |
2011 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The importance of dopamine D2 receptors (DRD2) for central nervous dopaminergic signalling makes variants in the DRD2 gene potential modulators of the risk or course of various behavioural, psychiatric or neurologic diseases (e.g. addiction, schizophrenia, Parkinson's disease).
|
19512960 |
2009 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients.
|
19396436 |
2009 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This study identified apomorphine use and levodopa dosages between 500 and 1000 mg as non-genetic and the 15× DRD2 CA repeat allele as genetic determinants for the discontinuation of non-ergoline DA treatment in patients with PD.
|
19669131 |
2009 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genotype combinations characterized by the presence of two variant genotypes on their corresponding loci revealed that four combinations of GSTT1 null and MnSOD(-9Val) or GST null and MAOB-G or CYP2E1*5B and MAO-B-AG or CYP2E1*5B and DRD2 (Taq1A-het) genotypes in the patients exhibited severalfold higher and significant association with risk to PD.
|
18327668 |
2008 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the DRD2 TaqIA polymorphism alone has no pivotal role for interindividual variability of dopaminergic requirement in PD.
|
18175338 |
2008 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
RGD |
Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats.
|
18289173 |
2008 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we investigated this effect in Parkinson's disease (PD) patients carrying the DRD2 TaqIA A1 allelic variant.
|
17147698 |
2007 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Previously, we found a significant association between the dopamine D2 receptor gene polymorphism Taq IA and sudden onset of sleep in patients with Parkinson disease.
|
16124668 |
2005 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, alterations in RGS9-2 may be a key factor in the pathway leading from D2DRs to the side effects associated with the treatment both of psychoses and Parkinson's disease.
|
15728856 |
2005 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Patients Two hundred fifty patients with Parkinson disease were screened for the presence or absence of PDD following a short-term levodopa administration, and 215 subjects were available for further evaluations, including genotypic analysis of the CA dinucleotide short tandem repeat (CAn-STR) polymorphism located in the dopamine receptor D2 gene (DRD2).
|
15824260 |
2005 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our results show a significant association between the dopamine D2 receptor gene polymorphism Taq IA and SOS in PD.
|
15390060 |
2004 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease.
|
12722176 |
2003 |
|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
No alteration in the level of dopamine D2 receptor or dopamine transporter mRNA was found in either lobule in patients with Parkinson's disease.
|
14622169 |
2003 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We tested for gender-specific interactions between smoking and genetic polymorphisms of monoamine oxidase B (MAO-B) intron 13 (G or A allele), monoamine oxidase A (MAO-A) EcoRV (Yor N allele), and dopamine D2 recepor (DRD2) Taq1B (B1 or B2 allele) in a case-control study of 186 incident idiopathic Parkinson's disease (PD) cases and 296 age- and gender-matched controls.
|
12428723 |
2002 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
MGD |
Activity, non-selective attention and emotionality in dopamine D2/D3 receptor knock-out mice.
|
11864730 |
2002 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The -141C Ins/Del polymorphism of the dopamine D2 receptor gene is not associated with either migraine or Parkinson's disease.
|
11409701 |
2001 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Further, DRD2 variants have been implicated in Parkinson's disease (PD) and in iatrogenically-induced movement disorders, as well as in certain migraineurs.
|
11256581 |
2000 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in the DRD2 gene may influence the risk of developing PD, thus confirming that the DRD2 gene is a susceptibility locus for PD.
|
10634251 |
2000 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the hypothesis that a TaqI repeat fragment length polymorphism in the dopamine D2 receptor gene may be associated with PD.
|
11104188 |
2000 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
MGD |
Neuroprotective role of dopamine against hippocampal cell death.
|
11069974 |
2000 |